---
title: "Lushang Freda Pharmaceutical Co.,Ltd. (600223.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600223.SH.md"
symbol: "600223.SH"
name: "Lushang Freda Pharmaceutical Co.,Ltd."
industry: "Personal Care Products"
datetime: "2026-03-07T10:48:46.346Z"
locales:
  - [en](https://longbridge.com/en/quote/600223.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600223.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600223.SH.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/600223.SH.md) | [繁體中文](https://longbridge.com/zh-HK/quote/600223.SH.md)


# Lushang Freda Pharmaceutical Co.,Ltd. (600223.SH)

## Company Overview

Lushang Freda Pharmaceutical Co.,Ltd. engages in the production and sales of pharmaceuticals, raw materials, and additives in China. The company is involved in cosmetics and medicine businesses. It provides cleansers, lotions, creams, essences, masks, and other products.

| Item | Detail |
|------|--------|
| Industry | Personal Care Products |
| Exchange | CN Market |
| Website | [www.lshfreda.com](https://www.lshfreda.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-07T04:30:13.000Z

**Overall: C (0.41)**

**Industry**: Personal Care Products

| Metric | Value |
|--------|-------|
| Industry Ranking | 17 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.26% |  |
| Net Profit YoY | -9.47% |  |
| P/B Ratio | 1.72 |  |
| Dividend Ratio | 0.85% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7217638302.50 |  |
| Revenue | 3776826928.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.18% | C |
| Profit Margin | 5.67% | C |
| Gross Margin | 49.75% | B |
| Revenue YoY | -5.26% | D |
| Net Profit YoY | -9.47% | D |
| Total Assets YoY | -4.43% | D |
| Net Assets YoY | 2.77% | C |
| Cash Flow Margin | 1763.99% | B |
| OCF YoY | -5.26% | D |
| Turnover | 0.63 | B |
| Gearing Ratio | 16.16% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Lushang Freda Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.26%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.47%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.72",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.85%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7217638302.50",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3776826928.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.18%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "5.67%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "49.75%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-5.26%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.47%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.43%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.77%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1763.99%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-5.26%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.63",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "16.16%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 33.71 | 11/27 | 36.44 | 35.44 | 33.76 |
| PB | 1.72 | 5/27 | 2.01 | 1.89 | 1.81 |
| PS (TTM) | 1.91 | 3/27 | 2.13 | 2.04 | 1.97 |
| Dividend Yield | 0.84% | 14/27 | 1.90% | 1.41% | 0.81% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Proya (603605.SH) | A | C | A | B | C | B |
| 02 | FLYCO (603868.SH) | B | D | A | A | C | B |
| 03 | TIANXIN PHARMA (603235.SH) | B | B | C | A | C | B |
| 04 | Marubi (603983.SH) | B | B | B | B | B | B |
| 05 | SYG (300740.SZ) | B | C | A | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.10 |
| Highest Target | 9.74 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600223.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600223.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600223.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600223.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**